menu
    • menu
    [{"orgOrder":0,"company":"Soleo Health","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Soleo Health"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Soleo Health"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Soleo Health"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Soleo Health"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Soleo Health"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Argenx"},{"orgOrder":0,"company":"Soleo Health","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"Immune Globulin Intravenous, Human","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ GC Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ GC Biopharma"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Mitsubishi Chemical Holdings Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Soleo Health"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Mitsubishi Chemical Holdings Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Soleo Health"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Soleo Health"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Partnership","leadProduct":"Inclisiran","moa":"PCSK9 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Soleo Health \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Immune Globulin (Human)","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Soleo Health \/ Grifols International","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Grifols International"}]

    Find Clinical Drug Pipeline Developments & Deals by Soleo Health

    Menu

    Soleo Health

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Immune Globulin Intravenous, Human

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : GC Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Soleo Health Selected as Specialty Pharmacy for ALYGLO™ for Adults with PI

                            Details : Soleo partnership with GC Biopharma to dispense Alyglo (Immune Globulin Intravenous, Human-stwk) 10% Liquid for treating Adults with Primary Humoral Immunodeficiency.

                            Product Name : Alyglo

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            July 16, 2024

                            Lead Product(s) : Immune Globulin Intravenous, Human

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : GC Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inclisiran

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Soleo Health Selected by Novartis as Limited Drug Distribution Partner for Administration of LEQVIO

                            Details : LEQVIO (inclisiran) injection is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH).

                            Product Name : Leqvio

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            July 26, 2022

                            Lead Product(s) : Inclisiran

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Mitsubishi Tanabe Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Soleo Health Named a Limited Drug Distribution Partner by Mitsubishi Tanabe Pharma America for RADICAVA ORS

                            Details : Specialty pharmacy partners to dispense nationwide RADICAVA ORS® (edaravone) oral suspension, commercialized by Mitsubishi Tanabe Pharma America, Inc. (MTPA), which commercializes approved pharmaceutical products in North America.

                            Product Name : Radicava

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 06, 2022

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Mitsubishi Tanabe Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Mitsubishi Tanabe Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mitsubishi Tanabe Pharma America Announces Long-Term Findings from Post-Marketing Safety Study of RADICAVA® (...

                            Details : RADICAVA® (edaravone) in a real-world setting during the first three years of availability in the United States (U.S.) for the treatment of amyotrophic lateral sclerosis (ALS).

                            Product Name : Radicava

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 29, 2022

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Mitsubishi Tanabe Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Mitsubishi Tanabe Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mitsubishi Tanabe Pharma America Presents Real-World Data on RADICAVA® (edaravone) at 2022 American Academy o...

                            Details : The analysis of real-world data suggest continued treatment of amyotrophic lateral sclerosis (ALS) patients with intravenous (IV) RADICAVA® (edaravone) resulted in a six-month longer median survival, compared to those not treated with the drug.

                            Product Name : Radicava

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 04, 2022

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Mitsubishi Tanabe Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efgartigimod Alpha

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Argenx

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Soleo Health Selected as Limited Distribution Partner for VYVGART™

                            Details : Soleo Health offers differentiated capabilities through its ability to collect real-world data and generate intelligent outcomes from VYVGART patients with its exclusive and proprietary clinical outcomes program, SoleMetrics®.

                            Product Name : Vyvgart

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            January 24, 2022

                            Lead Product(s) : Efgartigimod Alpha

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Argenx

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Mitsubishi Chemical Holdings Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mitsubishi Tanabe Pharma Post-Hoc Analysis of Phase 3 Study Examines Effect of Early Intervention with Edaravo...

                            Details : This post-hoc analysis assessed the double-blind, placebo-controlled 24-week Phase 3 study of edaravone, including an additional 24-week open-label period with all patients receiving IV edaravone.

                            Product Name : Radicava

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 18, 2021

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Mitsubishi Chemical Holdings Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Mitsubishi Chemical Holdings Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mitsubishi Tanabe Pharma America Presents Real-World Experience Outcomes During IV Edaravone Treatment

                            Details : Soleo Health's ability to collect specific data through its proprietary SoleMetrics patient outcomes program proved valuable in helping to elucidate real-world treatment patterns with IV edaravone in the U.S.

                            Product Name : Radicava

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 12, 2020

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Mitsubishi Chemical Holdings Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Mitsubishi Tanabe Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mitsubishi Tanabe Pharma America Announces Presentations At Northeast Amyotrophic Lateral Sclerosis 19th Annua...

                            Details : MTPA will present details on the REFINE-ALS study, assessing RADICAVA® (edaravone), for which MTPA aims to identify and measure specific biomarkers and clinical assessments in people with ALS.

                            Product Name : Radicava

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 30, 2020

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Mitsubishi Tanabe Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Soleo Health

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Mitsubishi Tanabe Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mitsubishi Tanabe Pharma America Announces the Global Phase 3 Study of Oral Edaravone for ALS has Completed En...

                            Details : The global multi-center, open-label study (MT-1186-A01), is evaluating approximately 185 ALS patients across approximately 50 sites in the U.S., Canada, Europe and Japan over the course of 48 weeks of treatment.

                            Product Name : Radicava

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 11, 2020

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Mitsubishi Tanabe Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth